Analysts Have Conflicting Sentiments on These Healthcare Companies: Novo Nordisk (NVO), Beam Therapeutics (BEAM) and TScan Therapeutics (TCRX)
Confident Investing Starts Here:
Novo Nordisk (NVO)
In a report issued on May 6, Evan Seigerman from BMO Capital maintained a Hold rating on Novo Nordisk, with a price target of $64.00. The company's shares closed last Friday at $67.35.
According to TipRanks.com, Seigerman is a 4-star analyst with an average return of 3.2% and a 42.7% success rate. Seigerman covers the Healthcare sector, focusing on stocks such as Structure Therapeutics, Inc. Sponsored ADR, Protagonist Therapeutics, and Arvinas Holding Company.
The word on The Street in general, suggests a Hold analyst consensus rating for Novo Nordisk with a $92.44 average price target.
BMO Capital analyst Kostas Biliouris maintained a Buy rating on Beam Therapeutics on May 7 and set a price target of $40.00. The company's shares closed last Friday at $16.83.
According to TipRanks.com, Biliouris has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -17.1% and a 29.2% success rate. Biliouris covers the Healthcare sector, focusing on stocks such as Centessa Pharmaceuticals, BioMarin Pharmaceutical, and Rocket Pharmaceuticals.
Beam Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $44.13, implying a 164.3% upside from current levels. In a report issued on May 6, William Blair also maintained a Buy rating on the stock.
TScan Therapeutics (TCRX)
BTIG analyst Jeet Mukherjee maintained a Buy rating on TScan Therapeutics on May 21 and set a price target of $12.00. The company's shares closed last Friday at $1.38, close to its 52-week low of $1.34.
According to TipRanks.com, Mukherjee has 0 stars on 0-5 stars ranking scale with an average return of -15.8% and a 31.6% success rate. Mukherjee covers the Healthcare sector, focusing on stocks such as Arvinas Holding Company, Janux Therapeutics Inc, and Carisma Therapeutics.
Currently, the analyst consensus on TScan Therapeutics is a Strong Buy with an average price target of $9.33, representing a 557.0% upside. In a report issued on May 6, TD Cowen also maintained a Buy rating on the stock.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Shares in Novo Nordisk rise after Wegovy gets US nod for liver disease treatment
By Jacob Gronholt-Pedersen COPENHAGEN, DENMARK (Reuters) -Shares in Novo Nordisk rose on Monday, after it got U.S. approval for its weight-loss drug Wegovy to treat a serious liver condition, positive news for the drugmaker that lost more than one-third of its market value in recent weeks. Novo's shares rose as much as 5% at opening and were trading 3.5% higher by 0711 GMT. Three weeks ago, investors wiped $70 billion off its market value, after Novo - which became Europe's most valuable listed company following the launch of Wegovy in 2021 - issued a profit warning and named a company veteran as new CEO. On Friday, the U.S. Food and Drug Administration granted accelerated approval for Wegovy to treat metabolic dysfunction-associated steatohepatitis, or MASH, making it the first GLP-1 class therapy cleared for the progressive liver condition that affects around 5% of adults in the United States. Rival Eli Lilly has published encouraging MASH data in a mid-stage trial with tirzepatide - the active ingredient in its popular diabetes drug Mounjaro and weight-loss treatment Zepbound. "It is expected that this market exclusivity will only last for a transitional phase before Eli Lilly also launches a product on the market," said Nordnet analyst Per Hansen. Novo has also applied this year for approval in Europe and Japan. Its shares have lost more than two-thirds of their value since June last year, amid concerns that the Danish drugmaker is losing ground in the obesity drug race it started to rival Eli Lilly and "compounded" copycat drugs. Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
Trending tickers: Novo Nordisk, Palo Alto Networks, Walmart, Soho House and Nio
Novo Nordisk ( NVO) Copenhagen-listed shares in pharmaceuticals giant Novo Nordisk ( rose nearly 4% on Monday morning, after the company announced that its blockbuster weight-loss drug Wegovy had been approved in the US to treat a form of liver disease. Novo ( said in an announcement on Friday that the US Food and Drug Administration (FDA) had approved Wegovy for the treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis, in combination with a reduced calorie diet and increased physical activity. Read more: Markets mixed as Zelensky and European leaders head to Washington for war talks The company said that accelerated approval is based on part one of a trial, in which Wegovy, demonstrated a statistically significant and superior improvement in liver fibrosis with no worsening of steatohepatitis, as well as resolution of steatohepatitis with no worsening of liver fibrosis compared to a placebo. The news offers a boost to Novo Nordisk ( which has been facing increasing competition in the weight-loss market, with shares in company currently down nearly 46% year-to-date. Martin Holst Lange, executive vice president, chief scientific officer and head of research and development at Novo ( said: "Wegovy is now uniquely positioned as the first and only GLP-1 treatment approved for MASH, complementing the already proven weight loss, cardiovascular benefits and extensive body of evidence linked to semaglutide." Palo Alto Networks (PANW) Shares in Palo Alto Networks (PANW) hovered just above the flatline in pre-market trading on Monday morning, ahead of the US cybersecurity company reporting its fourth quarter earnings later in the day. The company had guided to revenue for the quarter in the range of $2.49bn (£1.83bn) to $2.51bn, which would represent year-over-year growth of between 14% and 15%. Shares in the Palo Alto (PANW) came under pressure following the release of its third quarter earnings in May, as the results failed to impress investors. The cybersecurity company's third quarter revenue came in at $2.3bn, just above expectations, while adjusted earnings per share (EPS) were $0.80. Walmart (WMT) Shares in Walmart (WMT) were also trending on Monday, ahead of the company reporting its second quarter earnings on Thursday. Walmart's results are closely watched by investors as it is the largest retailer in the US, so it is considered to act as a barometer for consumer sentiment. The stock is up nearly 11% year-to-date but edged lower after Walmart (WMT) released a mixed set of first quarter results in May. Walmart (WMT) posted first quarter revenue of $165.5bn, which was up 2.5% from the same period last year, though this missed Wall Street expectations of $166.02bn. Adjusted earnings per share grew 1.7% year over year to $0.61, beating estimates of $0.58. US same-store sales also beat expectations with a 4.5% increase, led by health and wellness, and groceries. Stocks: Create your watchlist and portfolio John David Rainey, chief financial officer of Walmart (WMT), said in the earnings release that the company had decided to hold off on providing a specific range of guidance for operating income growth and earnings per share for the second quarter, given the "dynamic nature of the backdrop". Walmart (WMT) did guide to net sales growth of 3.5% to 4.5% for the quarter, based on the $167.8bn it reported a year ago. AJ Bell's (AJB.L) investment director Russ Mould and head of financial analysis Danni Hewson said that analysts expect a headline figure for net sales of $174bn. "That turns into a consensus analysts' forecasts for [net profit in] the second quarter of $5.8bn, and a headline earnings per share (EPS) figure of $0.72, up from $0.67 a year ago," they said. Soho House (SHCO) Shares in Soho House (SHCO) surged 13% in pre-market trading on Monday, following reports that the members' club was nearing a deal to go private. The Wall Street Journal reported on Sunday that a group of investors led by MCR Hotels was nearing a deal to take Soho House private. Read more: Stocks that are trending today They are reportedly expected to pay around $9 per share for the company's outstanding stock, with the deal valuing the company at $1.8bn. A spokeperson for Soho House (SHCO) had not responded to Yahoo Finance UK's request for comment at the time of writing. Nio ( NIO) Shares in Chinese electric vehicle company Nio ( jumped nearly 7% on Monday, after announcing it expansion into three new markets. Nio ( said in announcement on Monday that it planned to enter Singapore, Uzbekistan and Costa Rica in 2025 and 2026. Chris Chen, head of global business development at Nio ( said: "To accelerate our entry into diverse global markets, Nio is partnering with experienced players who have deep local expertise and extensive distributor networks. "They will help us introduce our high-quality smart electric vehicles to new markets more efficiently." Read more: Bank of England cuts gilt holdings by £32.5bn in second quarter The most popular stocks and funds investors bought in July UK job market continues to weaken as vacancies fall
Yahoo
an hour ago
- Yahoo
Shares in Novo Nordisk rise after Wegovy gets US nod for liver disease treatment
By Jacob Gronholt-Pedersen COPENHAGEN, DENMARK (Reuters) -Shares in Novo Nordisk rose on Monday, after it got U.S. approval for its weight-loss drug Wegovy to treat a serious liver condition, positive news for the drugmaker that lost more than one-third of its market value in recent weeks. Novo's shares rose as much as 5% at opening and were trading 3.5% higher by 0711 GMT. Three weeks ago, investors wiped $70 billion off its market value, after Novo - which became Europe's most valuable listed company following the launch of Wegovy in 2021 - issued a profit warning and named a company veteran as new CEO. On Friday, the U.S. Food and Drug Administration granted accelerated approval for Wegovy to treat metabolic dysfunction-associated steatohepatitis, or MASH, making it the first GLP-1 class therapy cleared for the progressive liver condition that affects around 5% of adults in the United States. Rival Eli Lilly has published encouraging MASH data in a mid-stage trial with tirzepatide - the active ingredient in its popular diabetes drug Mounjaro and weight-loss treatment Zepbound. "It is expected that this market exclusivity will only last for a transitional phase before Eli Lilly also launches a product on the market," said Nordnet analyst Per Hansen. Novo has also applied this year for approval in Europe and Japan. Its shares have lost more than two-thirds of their value since June last year, amid concerns that the Danish drugmaker is losing ground in the obesity drug race it started to rival Eli Lilly and "compounded" copycat drugs. Sign in to access your portfolio
